858.277.5678
Quality Patient Care. Exceptional Research.
News

Gilead announces SVR12 rates from three phase III studies evaluating a once-daily fixeddose combination of sofosbuvir and ledipasvir for genotype 1 hepatitis C patients

Download the PDF